Community/Retail

Jeff Fudin, PharmD, FCCP, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.

A report from IMS Institute for Healthcare Informatics finds that many pharmaceutical companies are lagging when it comes to engaging patients via social media.

Paying attention to how leaders in health-system pharmacy see the field changing can help one anticipate changes in other areas of pharmacy.

Patients who consistently used an online portal to refill their statin prescriptions had significantly increased medication adherence and improved LDL cholesterol control.

Mary Lynn McPherson, PharmD, explains how rescheduling hydrocodone combination products as Schedule II drugs will help reduce levels of abuse.

Jeff Fudin, PharmD, FCCP, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.

A new study estimates the costs of treating atrial fibrillation as well as the comparative costs of treating it with warfarin and newer oral anticoagulants.

Mary Lynn McPherson, PharmD, discusses why hydrocodone combination products were categorized as Schedule III in the first place.

A survey of pharmacy directors finds that they blame drug shortages for causing medication errors and adding to institutional costs.

If you really want to get your finances in order, you might want to consider going on an all-cash diet.

A study of COPD patients found that, on average, their exercise capacity declined over time and that just 5% enrolled in pulmonary rehabilitation, an intervention that has been shown to improve outcomes.

Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.

The agency has asked prescribers not to prescribe medications containing more than 325 mg of acetaminophen per dose.

Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.

University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

The risk of depression in chronic obstructive pulmonary disease patients increases along with disease severity, according to the results of a new study.

Martin R. Stämpfli, PhD, explains the development of COPD in his lecture at the seminar "COPD-Bridging the Gap between Science and Clinical Care."

One in 3 individuals is at risk for developing shingles.

A report finding little evidence of the benefits of medication therapy management is unlikely to be the final word on the topic.